Hallucinogenics in medicine
Dinah Kheder, Raju Haque, K. Romano
InnovAiT: Education and inspiration for general practice May 8, 2024 DOI: 10.1177/17557380241235646 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The authors describe hallucinogen risks such as muscle spasms, aggressive behaviour, convulsions, and unconsciousness, and note that most are schedule 1 drugs considered to have no therapeutic value, while arguing that research into their potential for depression, addiction, PTSD, and anxiety continues and that primary care clinicians should recognize these presentations. |
Abstract
Hallucinogenics are a broad category of psychoactive substances that have the ability to alter the senses of smell, taste, hearing and feeling, as well as mood and thought. They fall under three main categories: psychedelics, dissociatives and deliriants. Muscle spasms, aggressive behaviour, convulsions, and in some cases unconsciousness, are among the dangers associated with their use. Hallucinogenics are largely classified as schedule 1 drugs, and thus are considered to have no therapeutic value. However, global research into their therapeutic potential for conditions such as depression, addiction, post-traumatic stress disorder and anxiety is ongoing. This article aims to shed light on the risks associated with hallucinogenic substances, how this may present in primary care, and how they may be used in medicine in the future.